Abstract
BackgroundThe expression levels and clinical significances of Lysosomal-associated protein transmembrane-4β-35 (LAPTM4B-35) protein are unknown in the non-small-cell lung cancer (NSCLC). This study aimed to explore the expression and prognostic value of LAPTM4B-35 in NSCLC patients.MethodsThe clinicopathological and survival data of 107 NSCLC patients who received radical surgery from 2007 and 2011 were reviewed. The LAPTM4B-35 expression of the paired tumors and adjacent normal specimens were detected, and the association between LAPTM4B-35 and clinical variables was explored. Kaplan-Meier analysis and Cox regression (Proportional hazard model) were performed to investigate the prognostic significance for NSCLC.ResultsLAPTM4B-35 was over expressed in NSCLC tissues. The elevated LAPTM4B-35 expression was associated with cancer recurrence (P = 0.031). The 5-year median OS and PFS were significantly worse in the LAPTM4B-35 overexpressed group. Multivariate Cox analysis showed that LAPTM4B-35 over-expression was an independent factor for OS and PFS in NSCLC(P = 0.018, P = 0.026, respectively).ConclusionsThe overexpressed LAPTM4B-35 was an independent prognostic biomarker for NSCLC, which could predict cancer recurrence and poor over survival. And that may be applied as potential target for NSCLC treatment.
Highlights
Lung cancer was the mos important cause of tumorrelated death, though the incidence began declining in the last decades [1,2,3]
One study reported that Lysosome-associated protein transmembrane-4 beta (LAPTM4B) was elevated in Small cell lung cancer (SCLC) and its overexpression was an independent factor in SCLC prognosis [13]
LAPTM4B-35 was overexpressed in non-small-cell lung cancer (NSCLC) cancer tissues
Summary
Lung cancer was the mos important cause of tumorrelated death, though the incidence began declining in the last decades [1,2,3]. More novel and prognostic biomarkers that could predict the tumor recurrence and prognosis is still urgent to be identified to improve the prognosis of NSCLC [7]. One study reported that LAPTM4B was elevated in Small cell lung cancer (SCLC) and its overexpression was an independent factor in SCLC prognosis [13]. The expression levels and clinical significances of Lysosomalassociated protein transmembrane-4β-35 (LAPTM4B-35) protein are unknown in the non-small-cell lung cancer (NSCLC). Multivariate Cox analysis showed that LAPTM4B-35 over-expression was an independent factor for OS and PFS in NSCLC(P = 0.018, P = 0.026, respectively). Conclusions: The overexpressed LAPTM4B-35 was an independent prognostic biomarker for NSCLC, which could predict cancer recurrence and poor over survival. That may be applied as potential target for NSCLC treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
